Mereo BioPharma Ownership
| MREO Stock | USD 2.38 0.18 7.03% |
Mereo |
Mereo Stock Ownership Analysis
About 66.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.25. Mereo BioPharma Group had not issued any dividends in recent years. Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom. Mereo Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 49 people. To find out more about Mereo BioPharma Group contact Denise ScotsKnight at 44 33 3023 7300 or learn more at https://www.mereobiopharma.com.Mereo Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Mereo BioPharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Mereo BioPharma Group backward and forwards among themselves. Mereo BioPharma's institutional investor refers to the entity that pools money to purchase Mereo BioPharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ubs Group Ag | 2024-12-31 | 2.6 M | Tejara Capital Ltd | 2024-12-31 | 2.3 M | Goldman Sachs Group Inc | 2024-12-31 | 2.1 M | Renaissance Technologies Corp | 2024-12-31 | 1.2 M | Great Point Partners Llc | 2024-12-31 | 1.1 M | Perceptive Advisors Llc | 2024-12-31 | 1.1 M | Integral Health Asset Management, Llc | 2024-12-31 | 1000 K | Ubs Asset Mgmt Americas Inc | 2024-12-31 | 964.9 K | Tema Etfs | 2024-12-31 | 890.5 K | Hhg Plc | 2024-12-31 | 17.1 M | Rubric Capital Management Lp | 2024-12-31 | 15.3 M |
Mereo BioPharma Group Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Mereo BioPharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Mereo BioPharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Mereo BioPharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Mereo BioPharma Outstanding Bonds
Mereo BioPharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Mereo BioPharma Group uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Mereo bonds can be classified according to their maturity, which is the date when Mereo BioPharma Group has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US58942HAC51 Corp BondUS58942HAC51 | View | |
| MERCURY GEN P Corp BondUS589400AB62 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Mereo BioPharma Corporate Filings
| 12th of February 2025 Other Reports | ViewVerify | |
F4 | 6th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 23rd of January 2025 Other Reports | ViewVerify | |
8K | 13th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Pair Trading with Mereo BioPharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Mereo BioPharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mereo BioPharma will appreciate offsetting losses from the drop in the long position's value.Moving together with Mereo Stock
Moving against Mereo Stock
| 0.82 | WM | Waste Management | PairCorr |
| 0.77 | LUCD | Lucid Diagnostics | PairCorr |
| 0.73 | GE | GE Aerospace | PairCorr |
| 0.53 | PLX | Protalix Biotherapeutics | PairCorr |
| 0.5 | PG | Procter Gamble | PairCorr |
The ability to find closely correlated positions to Mereo BioPharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Mereo BioPharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Mereo BioPharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Mereo BioPharma Group to buy it.
The correlation of Mereo BioPharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Mereo BioPharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Mereo BioPharma Group moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Mereo BioPharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mereo BioPharma Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mereo BioPharma. If investors know Mereo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mereo BioPharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Mereo BioPharma Group is measured differently than its book value, which is the value of Mereo that is recorded on the company's balance sheet. Investors also form their own opinion of Mereo BioPharma's value that differs from its market value or its book value, called intrinsic value, which is Mereo BioPharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mereo BioPharma's market value can be influenced by many factors that don't directly affect Mereo BioPharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mereo BioPharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mereo BioPharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mereo BioPharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.